Vomit Medicine For Cancer Patients: Research is going on continuously for the treatment of cancer, scientists are testing new drugs, as well as trying many methods. In this list, a new study has found that if some cancer patients, including breast and pancreatic, are given drugs to stop vomiting or nausea at the time of surgery, then the life of the victim can be extended for some time. Is. According to the news report published in Dainik Jagran newspaper, Study has been presented in the Annual Meeting of Anesthesiology 2021 (ANESTHESIOLOGY 2021 annual meeting). During this research it was found that patients who died 3 months after surgery were 3 times more likely to take dexamethasone medicine than those who did not take this medicine. Let us tell you that the drug Dexamethasone is given to patients after surgery or chemotherapy to stop vomiting.
Researchers found that non-immunogenic cancer, ie in which a strong immune response is not catalyzed. There is a medium to long term benefit of dexamethasone drug in their patients. It can give relief to cancer patients of breast, uterus, ovary, oesophagus, pancreas, thyroid, bones and joints.
What do the researchers say?
Maximilian Schaefer, senior author of this research and director of the Center for Anesthesia Research Excellence, told that Dexamethasone has both good and bad effects. This drug not only stops the growth of cancer, but also suppresses the activation of the immune system.
Maximilian Schaefer said, “Earlier studies have shown that in cancers in which the immune system controls the disease, the positive and negative effects of dexamethasone in a way balance each other, so there is no benefit. . But in our large-scale studies, it has been seen that in the types of cancer in which the immune system does not play a significant role, its positive effect remains effective.
This is the conclusion of the study
During the study, 25,178 (34 percent) patients were given dexamethasone medication during surgery. Of these, 209 (0.83 percent) patients died 90 days after surgery. Whereas, of the patients who were not given dexamethasone medicine, 1,543 (3.2 percent) died. In addition, it was also found that after including other factors, younger patients who were regularly given dexamethasone medication had a 21 percent lower risk of death at one year.
The best effect of dexamethasone was observed in patients with cancer of the ovary, uterus or cervix. Schaefer said that based on our study, anesthesiologists should use dexamethasone without any hesitation in surgery for non-immunogenic cancer.